Insulet is disrupting how patients can treat their diabetes, capitalizing on its differentiated Omnipod on-the-body delivery technology, CEO Jim Hollingshead explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Hollingshead sits down with BI analyst Matt Henriksson for an in-depth interview on Insulet’s Omnipod patch pump technology, how on-the-body wear compares with traditional insulin pumps and opens access to patients still using syringes, and upcoming developments to expand its automated insulin-delivery technology to Type 2 diabetic patients.

<p>Insulet is disrupting how patients can treat their diabetes, capitalizing on its differentiated Omnipod on-the-body delivery technology, CEO Jim Hollingshead explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Hollingshead sits down with BI analyst Matt Henriksson for an in-depth interview on Insulet’s Omnipod patch pump technology, how on-the-body wear compares with traditional insulin pumps and opens access to patients still using syringes, and upcoming developments to expand its automated insulin-delivery technology to Type 2 diabetic patients.</p>

Vanguards of Healthcare is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

<p>Vanguards of Healthcare is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.</p>

Vanguards of Healthcare by Bloomberg Intelligence

Insulet Leads Insulin-Patch Pump Drive

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/a01cb2b7-b18a-4b68-ab13-b0ee01672772/transcript